Top Markets
Coin of the day
NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP
Ранг среди акций #18268
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Цена акции
$1.79
Последняя синхронизация: 2026-09-02
Рыночная капитализация
$205.75M
Изменение (1 день)
3.18%
Изменение (1 год)
-61.61%
Страна
US
Торговля NovaBridge Biosciences (NBP)

Категория

История цены акций NovaBridge Biosciences (NBP)
Наивысшая цена закрытия: $1.76 2026-09-01

Наименьшая цена закрытия: $13.69 2020-01-01
История цены акций NovaBridge Biosciences с 2020 по 2026
Годовая динамика цены акций
Год Результативность
2026 (TTM) -24.42%
2025 320.81%
2024 -37.56%
2023 -57.87%
2022 -92.59%
2021 24.83%
2020 0.00%
Цена акций похожих компаний или конкурентов
Компания Цена акций Изменение 1г% Страна
$556.43 40.29%
US
$1.05K 45.39%
NL
$152.82 535.43%
US
$123.37 -8.71%
AU
$757.71 6.76%
CH